DNAnexus Overview
- Year Founded
-
2009

- Status
-
Private
- Employees
-
286

- Latest Deal Type
-
Series I
- Latest Deal Amount
-
$200M
- Investors
-
23
DNAnexus General Information
Description
Developer of a biomedical informatics and data management platform designed to analyze DNA-sequencing data. The company's platform assists researchers across a spectrum of industries like biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia to accelerate their genomics programs globally, enabling commercial and academic medical researchers to visualize and analyze big data systems for DNA from a single, unified system.
Contact Information
Website
www.dnanexus.comCorporate Office
- 1975 West El Camino Real
- Suite 204
- Mountain View, CA 94040
- United States
Corporate Office
- 1975 West El Camino Real
- Suite 204
- Mountain View, CA 94040
- United States
DNAnexus Timeline
DNAnexus Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
12. Later Stage VC (Series I) | 08-Mar-2022 | $200M | Completed | Generating Revenue | ||
11. Later Stage VC (Series H) | 15-Mar-2021 | Completed | Generating Revenue | |||
10. Later Stage VC (Series G) | 06-Feb-2019 | Completed | Generating Revenue | |||
9. Later Stage VC (Series F) | 02-Jan-2018 | Completed | Generating Revenue | |||
8. Later Stage VC (Series E) | Completed | Generating Revenue | ||||
7. Debt - General | 01-May-2017 | Completed | Generating Revenue | |||
6. Later Stage VC (Series D) | 22-Apr-2015 | Completed | Generating Revenue | |||
5. Debt - General | 21-Mar-2014 | Completed | Generating Revenue | |||
4. Later Stage VC (Series C) | 03-Jan-2014 | $15M | $31.7M | Completed | Startup | |
3. Early Stage VC (Series B) | 12-Oct-2011 | $15.2M | $16.7M | Completed | Startup |
DNAnexus Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series I | ||||||||
Series H | ||||||||
Series G | ||||||||
Series F-2 | ||||||||
Series F-1 | ||||||||
Series E | ||||||||
Series D | ||||||||
Series C | ||||||||
Series B | 7,559,292 | $0.001000 | $0.16 | $2.02 | $2.02 | 1x | $0.63 | 2.37% |
Series A | 1,347,823 | $0.001000 | $0.09 | $1.15 | $1.15 | 1x | $0.47 | 0.32% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
DNAnexus Comparisons
Industry
Financing
Details
DNAnexus Competitors (35)
One of DNAnexus’s 35 competitors is Benchling, a Venture Capital-Backed company based in San Francisco, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Benchling | Venture Capital-Backed | San Francisco, CA | ||||
PointCross Life Sciences | Venture Capital-Backed | Foster City, CA | ||||
SOPHiA GENETICS | Formerly VC-backed | Rolle, Switzerland | ||||
Gene By Gene | Formerly VC-backed | Houston, TX | ||||
BC Platforms | Private Equity-Backed | Zurich, Switzerland |
DNAnexus Patents
DNAnexus Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170237805-A1 | Worker reuse deadline | Inactive | 12-Feb-2016 | ||
US-20170177597-A1 | Biological data systems | Inactive | 22-Dec-2015 | ||
US-20140249761-A1 | Characterizing uncharacterized genetic mutations | Inactive | 01-Mar-2013 | ||
US-20150331909-A1 | Application programming interface for tabular genomic datasets | Inactive | 20-Dec-2012 | ||
US-20140244625-A1 | Sequence read archive interface | Inactive | 12-Aug-2011 | G16B50/00 |
DNAnexus Signals
DNAnexus Investors (23)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Blackstone | PE/Buyout | Minority | ||
Ally Bridge Group | PE/Buyout | Minority | ||
Northpond Ventures | Venture Capital | Minority | ||
Perceptive Advisors | Venture Capital | Minority | ||
Regeneron Pharmaceuticals | Corporation | Minority |
DNAnexus FAQs
-
When was DNAnexus founded?
DNAnexus was founded in 2009.
-
Where is DNAnexus headquartered?
DNAnexus is headquartered in Mountain View, CA.
-
What is the size of DNAnexus?
DNAnexus has 286 total employees.
-
What industry is DNAnexus in?
DNAnexus’s primary industry is Discovery Tools (Healthcare).
-
Is DNAnexus a private or public company?
DNAnexus is a Private company.
-
What is the current valuation of DNAnexus?
The current valuation of DNAnexus is
. -
What is DNAnexus’s current revenue?
The current revenue for DNAnexus is
. -
How much funding has DNAnexus raised over time?
DNAnexus has raised $611M.
-
Who are DNAnexus’s investors?
Blackstone, Ally Bridge Group, Northpond Ventures, Perceptive Advisors, and Regeneron Pharmaceuticals are 5 of 23 investors who have invested in DNAnexus.
-
Who are DNAnexus’s competitors?
Benchling, PointCross Life Sciences, SOPHiA GENETICS, Gene By Gene, and BC Platforms are some of the 35 competitors of DNAnexus.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »